Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock - CYCCP STOCK NEWS

Cyclacel Pharmaceuticals reported second quarter 2022 financial results, highlighting the progress of oral fadraciclib, a CDK2 and CDK9 inhibitor. The drug demonstrated good tolerability and early efficacy in solid tumors and lymphomas, with plans to enter Phase 2 proof-of-concept in 2H 2022. Cash and equivalents totaled $29.1 million, expected to fund operations into 2H 2023. R&D expenses were $4.2 million, with a net loss of $4.6 million. A conference call is scheduled for August 10, 2022.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will announce its second quarter 2022 financial results on August 10, 2022. The company focuses on developing innovative cancer medicines, including fadraciclib and CYC140. A conference call will take place at 4:30 p.m. EDT on the same day, which will include a live webcast and archived audio options. Cyclacel acknowledges risks related to its clinical trials and product candidates, as specified in their forward-looking statements.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced the completion of enrollment in its Phase 1 dose escalation study of oral fadraciclib in solid tumors. No dose limiting toxicities were reported, and evidence shows target engagement for CDK2 and CDK9. Early anticancer activity was noted, with patients experiencing partial responses and stable disease across various cancers, including endometrial and pancreatic cancers. The company plans an R&D Day in fall 2022 to share more data.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors, representing 6% Convertible Exchangeable Preferred stockholders. Dr. Ferguson brings over 30 years of drug development experience, previously serving as Chief Scientific Officer at EMulate Therapeutics and Chief Development Officer at Omeros Corp. He is expected to provide valuable insights for Cyclacel’s clinical development programs, particularly for its promising cancer therapies, fadraciclib and CYC140, currently in Phase 1/2 clinical studies.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) reported strong advancements in its clinical trials for oral fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor, during Q1 2022. Both candidates are in Phase 1/2 studies with promising safety profiles. Fadraciclib has shown effective suppression of MCL1 in chronic lymphocytic leukemia, while CYC140 is expected to demonstrate activity across various solid tumors. The company has a pro forma cash balance of $34.5 million and anticipates funding its operations through mid-2023. A conference call is scheduled for May 11, 2022.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, CYCCP) will announce its first quarter 2022 financial results on May 11, 2022. A conference call and live webcast will take place at 4:30 p.m. EDT on the same day. Cyclacel specializes in developing innovative cancer medicines targeting cell cycle and transcriptional regulation. Their current projects include fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor, aimed at treating solid tumors and hematological malignancies. The webcast will be available for 90 days after the event.

Cyclacel Pharmaceuticals has commenced a multi-cohort Phase 1/2 study for CYC140, a potent PLK1 inhibitor, targeting advanced solid tumors and lymphomas. The first patient has been dosed, with trials set to evaluate safety, tolerability, and efficacy. Initial data are expected in H1 2023. The trial, CYC140-101, aims to establish an optimal dosing regimen and will involve various cancer types, including those with specific genetic mutations. CYC140 shows promise in preclinical studies, indicating potential new treatment options for resistant cancer types.

Cyclacel Pharmaceuticals announced significant preclinical data for its CDK2/9 inhibitor fadraciclib, which demonstrates its potential in treating chronic lymphocytic leukemia (CLL) and synergy with venetoclax.

Research from the University of Texas MD Anderson shows fadraciclib reduces anti-apoptotic protein MCL1 and induces apoptosis, particularly in 17p deleted CLL cells. These findings support ongoing Phase 1/2 clinical trials for fadraciclib in combination therapies. The company aims to enhance treatment options for patients resistant to current therapies.

Cyclacel Pharmaceuticals reported its financial results for Q4 and full year 2021, showing a net loss of $18.9 million, up from $8.4 million in 2020. Cash equivalents increased to $36.6 million, projected to last through mid-2023. The Phase 1/2 study of fadraciclib in solid tumors is ongoing, with initial data expected in the first half of 2022. The company is also initiating a Phase 1/2 study for oral CYC140. Key clinical milestones are anticipated throughout 2022, supporting its position as a contender in cancer treatment.